Effect of suicide gene therapy in combination with immunotherapy on antitumour immune response & tumour regression in a xenograft mouse model for head & neck squamous cell carcinoma

Indian Journal of Medical Research

Volumn 132, Issue 10, 2010, Pages 415-422

  Ambade, Aditya V ^a   Joshi, Ganesh V ^a   Mulherkar, Rita ^a  

^a TATA MEMORIAL HOSPITAL   (India)

Author keywords

Gene therapy; HNSCC; Interleukin 2; Naked DNA injection; Prodrug suicide gene therapy; Thymidine kinase

Indexed keywords

CASPASE 3; GANCICLOVIR; GLYCOPROTEIN P 15095; INTERLEUKIN 2; PLASMID DNA; THYMIDINE KINASE;

ANALYSIS OF VARIANCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER GENE THERAPY; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CELL ACTIVITY; CELL PROLIFERATION; CONTROLLED STUDY; DENDRITIC CELL; FLOW CYTOMETRY; GENE DIRECTED ENZYME PRODRUG THERAPY; HEAD AND NECK CARCINOMA; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IN VIVO GENE TRANSFER; IN VIVO STUDY; KRUSKAL WALLIS TEST; MOUSE; NATURAL KILLER CELL; NONHUMAN; SQUAMOUS CELL CARCINOMA; SUICIDE GENE THERAPY; TUMOR VOLUME; TUMOR XENOGRAFT; ANIMAL; CELL LINE; DRUG EFFECT; DRUG SCREENING; GENE THERAPY; GENE VECTOR; GENETICS; HEAD AND NECK TUMOR; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; METHODOLOGY; NICK END LABELING; NONPARAMETRIC TEST; RETROVIRUS; SUICIDE TRANSGENE;

ANALYSIS OF VARIANCE; ANIMALS; CARCINOMA, SQUAMOUS CELL; CELL LINE; CELL PROLIFERATION; DENDRITIC CELLS; FLOW CYTOMETRY; GENE THERAPY; GENES, TRANSGENIC, SUICIDE; GENETIC VECTORS; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOTHERAPY; IN SITU NICK-END LABELING; INTERLEUKIN-2; KILLER CELLS, NATURAL; MICE; RETROVIRIDAE; STATISTICS, NONPARAMETRIC; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 78049460787     PISSN: 09715916     EISSN: 09715916     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Edwards BK, Brown ML, Wingo PA, Howe HL, Ward E, Ries LA, et al. Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment. J Natl Cancer Inst 2005; 97: 1407-1427.
2. Kurkure AP, Yeole BB. Social inequalities in cancer with special reference to South Asian countries. Asian Pac J Cancer Prev 2006; 7: 36-40.
3. Moolten FL. Drug sensitivity ("suicide") genes for selective cancer chemotherapy. Cancer Gene Ther 1994; 1: 279-287.
4. Moolten FL, Wells JM. Curability of tumors bearing herpes thymidine kinase genes transferred by retroviral vectors. J Natl Cancer Inst 1990; 82: 297-300.
5. Thomas SM, Naresh KN, Wagle AS, Mulherkar R. Preclinical studies on suicide gene therapy for head/neck cancer: a novel method for evaluation of treatment efficacy. Anticancer Res 1998; 18: 4393-4398.
6. Mullen CA, Anderson L, Woods K, Nishino M, Petropoulos D. Ganciclovir chemoablation of herpes thymidine kinase suicide gene-modified tumors produces tumor necrosis and induces systemic immune responses. Hum Gene Ther 1998; 9: 2019-2030.
7. Hall SJ, Sanford MA, Atkinson G, Chen SH. Induction of potent antitumor natural killer cell activity by herpes simplex virus-thymidine kinase and ganciclovir therapy in an orthotopic mouse model of prostate cancer. Cancer Res 1998; 58: 3221-3225.
8. Mulherkar R, Goud AP, Wagle AS, Naresh KN, Mahimkar MB, Thomas SM, et al. Establishment of a human squamous cell carcinoma cell line of the upper aero-digestive tract. Cancer Lett 1997; 118: 115-121.
9. Ambade A, Mulherkar R. Adoptive T cell transfer augments IL-2 mediated tumour regression in a HNSCC xenograft nude mouse model. Cancer Lett 2008; 272: 316-324.
10. Veelken H, Re D, Kulmburg P, Rosenthal FM, Mackensen A, Mertelsmann R, et al. Systematic evaluation of chimeric marker genes on dicistronic transcription units for regulated expression of transgenes in vitro and in vivo. Hum Gene Ther 1996; 7: 1827-1836.
11. Wagle AS, Joshi GV, Naresh KN, Mulherkar R. Preclinical studies for gene therapy of head and neck cancers using the HSV-tk/GCV strategy. Indian J Biotechnol 2005; 4: 82-87.
12. Hoatlin ME, Kozak SL, Spiro C, Kabat D. Amplified and tissue-directed expression of retroviral vectors using ping-pong techniques. J Mol Med 1995; 73: 113-120.
13. Ghiringhelli PD, Romanowski V. Quick methylene blue staining for visualizing virus plaques in titration experiments. Biotechniques 1994; 17: 464-5.
14. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 1990; 82: 1107-1112.
15. Yazawa K, Fisher WE, Brunicardi FC. Current progress in suicide gene therapy for cancer. World J Surg 2002; 26: 783-789.
16. Park K, Kim WJ, Cho YH, Lee YI, Lee H, Jeong S, et al. Cancer gene therapy using adeno-associated virus vectors. Front Biosci 2008; 13: 2653-2659.
17. Edelstein ML, Abedi MR, Wixon J. Gene therapy clinical trials worldwide to 2007-an update. J Gene Med 2007; 9: 833-842.
18. Klatzmann D, Valery CA, Bensimon G, Marro B, Boyer O, Mokhtari K, et al. A phase I/II study of herpes simplex virus type 1 thymidine kinase "suicide" gene therapy for recurrent glioblastoma. Study Group on Gene Therapy for Glioblastoma. Hum Gene Ther 1998; 9: 2595-2604.
19. Long Z, Li LP, Grooms T, Lockey C, Nader K, Mychkovsky I, et al. Biosafety monitoring of patients receiving intracerebral injections of murine retroviral vector producer cells. Hum Gene Ther 1998; 9: 1165-1172.
20. Kanazawa T, Mizukami H, Okada T, Hanazono Y, Kume A, Nishino H, et al. Suicide gene therapy using AAV-HSVtk/ganciclovir in combination with irradiation results in regression of human head and neck cancer xenografts in nude mice. Gene Ther 2003; 10: 51-58.
21. Freytag SO, Stricker H, Pegg J, Paielli D, Pradhan DG, Peabody J, et al. Phase I study of replication-competent adenovirus-mediated double-suicide gene therapy in combination with conventional-dose three-dimensional conformal radiation therapy for the treatment of newly diagnosed, intermediate- to high-risk prostate cancer. Cancer Res 2003; 63: 7497-7506.
22. Kieback DG, Fischer DC, Engehausen DG, Sauerbrei W, Oehler MK, Tong XW, et al. Intraperitoneal adenovirus-mediated suicide gene therapy in combination with either topotecan or paclitaxel in nude mice with human ovarian cancer. Cancer Gene Ther 2002; 9: 478-481.
23. Clayman GL, Frank DK, Bruso PA, Goepfert H. Adenovirus-mediated wild-type p53 gene transfer as a surgical adjuvant in advanced head and neck cancers. Clin Cancer Res 1999; 5: 1715-1722.
24. Contassot E, Ferrand C, Certoux JM, Reynolds CW, Jacob W, Chiang Y, et al. Retrovirus-mediated transfer of the herpes simplex type I thymidine kinase gene in alloreactive T lymphocytes. Hum Gene Ther 1998; 9: 73-80.
25. Colombo F, Barzon L, Franchin E, Pacenti M, Pinna V, Danieli D, et al. Combined HSV-TK/IL-2 gene therapy in patients with recurrent glioblastoma multiforme: biological and clinical results. Cancer Gene Ther 2005; 12: 835-848.
26. Okada H, Pollack IF, Lotze MT, Lunsford LD, Kondziolka D, Lieberman F, et al. Gene therapy of malignant gliomas: a phase I study of IL-4-HSV-TK gene-modified autologous tumor to elicit an immune response. Hum Gene Ther 2000; 11: 637-653.
27. Marktel S, Magnani Z, Ciceri F, Cazzaniga S, Riddell SR, Traversari C, et al. Immunologic potential of donor lymphocytes expressing a suicide gene for early immune reconstitution after hematopoietic T-cell-depleted stem cell transplantation. Blood 2003; 101: 1290-1298.
28. Vile RG, Castleden S, Marshall J, Camplejohn R, Upton C, Chong H. Generation of an anti-tumour immune response in a non-immunogenic tumour: HSVtk killing in vivo stimulates a mononuclear cell infiltrate and a Th1-like profile of intratumoural cytokine expression. Int J Cancer 1997; 71: 267-274.
29. Majumdar AS, Zolotorev A, Samuel S, Tran K, Vertin B, Hall-Meier M, et al. Efficacy of herpes simplex virus thymidine kinase in combination with cytokine gene therapy in an experimental metastatic breast cancer model. Cancer Gene Ther 2000; 7: 1086-1099.
30. Brockstedt DG, Diagana M, Zhang Y, Tran K, Belmar N, Meier M, et al. Development of anti-tumor immunity against a non-immunogenic mammary carcinoma through in vivo somatic GM-CSF, IL-2, and HSVtk combination gene therapy. Mol Ther 2002; 6: 627-636.
31. Barzon L, Pacenti M, Franchin E, Colombo F, Palu G. HSV-TK/IL-2 gene therapy for glioblastoma multiforme. Methods Mol Biol 2009; 542: 529-549.